Why the study?
Does the IMS-Digoxin assay prevent false elevation of digoxin levels by endogenous digoxin-like immunoreactive factors compared to FPIA?
Population
60 specimens
Comparison
Enzyme-linked immunosorbent digoxin assay on the… vs Fluorescence polarization immunoassay and…
Design
Cross-sectional
Authors
Loading...
IMS-Digoxin may avoid FPIA false positives from DLIF; leaves open whether assay selection improves clinical monitoring or outcomes.
Does the IMS-Digoxin assay prevent false elevation of digoxin levels by endogenous digoxin-like immunoreactive factors compared to FPIA?
The new IMS-Digoxin assay is free from interference by endogenous digoxin-like immunoreactive factors, preventing the falsely elevated digoxin measurements commonly seen with FPIA methods.
Dasgupta et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: